SynAct Pharma

SynAct Pharma is pioneering a resolution therapy approach to inflammation, moving beyond traditional immunosuppression. Its lead asset, resomelagon, is a first-in-class, biased agonist of melanocortin receptors 1 and 3, currently in Phase 2b development for rheumatoid arthritis and Phase 2 for Dengue fever. The company's strategy aims to create a new standard of care across a wide inflammatory disease spectrum by promoting the body's natural healing processes. With a pipeline that includes an injectable peptide candidate, SynAct is positioning itself at the forefront of a novel therapeutic paradigm.

Platform of selective melanocortin receptor (MC1r and MC3r) agonists designed to resolve inflammation by activating the body's natural pro-resolving pathways, promoting immune homeostasis without immunosuppression.

SynAct operates in the highly competitive immunology space, competing against entrenched biologic therapies and newer oral JAK inhibitors. Its primary differentiation is its resolution-based mechanism aiming to avoid immunosuppression. It faces competition from other companies exploring pro-resolving mediators (e.g., SPM analogs) and novel anti-inflammatory targets, but its specific focus on oral melanocortin agonists is unique.